{"url_path":"/sec/cvkd/8-k/2026-07-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1937993/0001213900-26-079824-index.html","accession_number":"0001213900-26-079824","cik":"0001937993","ticker":"CVKD","issuer_name":"Cadrenal Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1937993/0001213900-26-079824-index.html","primary_entity_key":"0001937993","primary_entity_name":"Cadrenal Therapeutics, Inc."},"word_count":170,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nJuly 21, 2026, Cadrenal Therapeutics, Inc. (the “Company”) issued a press release announcing a comprehensive alignment of\nits clinical portfolio into a Cardiac Acute Critical Care Franchise and the initiation of a structured process to secure strategic out-licensing,\nportfolio monetization, or commercial co-development partnerships for its late-stage assets.\n\n  \n\nA\ncopy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 7.01 and in the press release furnished\nas Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities\nAct of 1933, as amended, and shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the\n“SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language\nin such filing."}